Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial

Addiction

Volumn 111, Issue 4, 2016, Pages 695-705

  Hser, Yih Ing ^a   Evans, Elizabeth ^a   Huang, David ^a   Weiss, Robert ^a   Saxon, Andrew ^b   Carroll, Kathleen M ^c   Woody, George ^d   Liu, David ^e   Wakim, Paul ^e   Matthews, Abigail G ^f   Hatch Maillette, Mary ^g   Jelstrom, Eve ^f   Wiest, Katharina ^h   Mclaughlin, Paul ⁱ   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^f EMMES CORPORATION   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h CODA Inc ^*  (United States)

ⁱ Hartford Dispensary   (United States)

Author keywords

Buprenorphine; Longitudinal; Methadone; Mortality; Opioid dependence; Opioid use; Outcomes

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE, NALOXONE DRUG COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RANDOM ALLOCATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961184596     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13238     Document Type: Article

References (29)

1. Hser Y. I., Evans E., Grella C., Ling W., Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry 2015; 23: 76-89.
2. NIH Consensus Statement. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280: 1963-43.
3. Bell J., Trinh L., Butler B., Randall D., Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 1193-200.
4. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor RJ., Fry-Smith A., Day E., Lintzeris N., Roberts T., Burls A., Taylor RS. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171. iii-iv. Review. PubMed PMID: 17313907.
5. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
6. Garcia-Portilla M. P., Bobes-Bascaran M. T., Bascaran M. T., Saiz P. A., Bobes J. Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? Br J Clin Pharmacol 2014; 77: 272--284.
7. Connery H. S. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry 2015; 23: 63-75.
8. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012; 31: 207-25.
9. Kleber H. D. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9: 455-70.
10. Saxon A. J., Ling W., Hillhouse M., Thomas C., Hasson A., Ang A., Doraimani G., Tasissa G., Lokhnygina Y., Leimberger J., Bruce R.D., McCarthy J., Wiest K., McLaughlin P., Bilangi R., Cohen A., Woody G., Jacobs P. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128: 71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22. PubMed PMID: 22921476; PubMed Central PMCID: PMC3543467.
11. Hser Y. I., Saxon A. J., Huang D., Hasson A., Thomas C., Hillhouse M., Jacobs P., Teruya C., McLaughlin P., Wiest K., Cohen A., Ling W. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109: 79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9. PubMed PMID: 23961726; PubMed Central PMCID: PMC3947022.
12. Sobell L. C., Sobell M. B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J. P., editors. Measuring Alcohol Consumption. Totowa, NJ: Humana Press; 1992, pp. 41-72.
13. Hser Y., Anglin M. D., Chou C. P. Reliability of retrospective self-report by heroin addicts. Psychol Assess 1992; 4: 207-13.
14. Murphy D., Hser Y., Huang D., Brecht L., Herbeck D. M. Self-report of longitudinal substance use: a comparison of the UCLA natural history interview and the Addiction Severity Index. J Drug Issues 2010; 40: 495-516.
15. Cohen J. Statistical Power Analysis for Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Earlbaum; 1988.
16. Weiss R. E. Modeling Longitudinal Data. New York: Springer; 2005.
17. SAS Institute Inc. SAS/STAT(R) 9.3 User's Guide: The MIXED Procedure. Cary, NC: SAS Institute Inc; 2011.
18. Teruya C., Schwartz R. P., Mitchell S. G., Hasson A. L., Thomas C., Buoncristiani S. H. et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoact Drugs 2014; 46: 412-26.
19. Haddad M. S., Zelenev A., Altice F. L. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend 2013; 131: 127-35.
20. Jaremko K. M., Sterling R. C., Van Bockstaele E. J. Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance. J Subst Abuse Treat 2015; 48: 117-27.
21. Bentzley B. S., Barth K. S., Back S. E., Book S. W. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat 2015; 52: 48-57.
22. Rich J. D., McKenzie M., Larney S., Wong J. B., Tran L., Clarke J. et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet 2015; 386: 350-9.
23. Booth B. M., Leukefeld C., Falck R., Wang J., Carlson R. Correlates of rural methamphetamine and cocaine users: results from a multistate community study. J Stud Alcohol 2006; 67: 493-501.
24. Sumnall H. R., Wagstaff G. F., Cole J. C. Self-reported psychopathology in polydrug users. J Psychopharmacol 2004; 18: 75-82.
25. Patterson T. L., Semple S. J., Zians J. K., Strathdee S. A. Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use. J Urban Health 2005; 82: i120-6.
26. John D., Kwiatkowski C. F., Booth R. E. Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry. Drug Alcohol Depend 2001; 64: 165-72.
27. Bovasso G., Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res 2003; 30: 290-303.
28. Williamson A., Darke S., Ross J., Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug Alcohol Depend 2006; 28: 293-300. (accessed 11 December 2015)
29. Lipari R. N., Hughes A. The NSDUH Report: Trends in Heroin Use in the United States: 2002 to 2013. 2015. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Rockville, MD. Available at: http://www.webcitation.org/6dhbHb7dJ on 11 December 2015